含贝达喹啉方案治疗非结核分枝杆菌病三例

doi:10.19982/j.issn.1000-6621.20230132

摘要/Abstract

中图分类号:

R563

王庆, 丁彩红, 高绪胜, 解丹, 蒋培培, 熊瑜. 含贝达喹啉方案治疗非结核分枝杆菌病三例[J]. 中国防痨杂志, 2023, 45(8): 814-817. doi: 10.19982/j.issn.1000-6621.20230132

图/表 3

图1~5

图17~20

图25

参考文献 19

[1]	Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J, 2020, 56(1): 2000535. doi:10.1183/13993003.00535-2020. doi: 10.1183/13993003.00535-2020
[2]	中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020, 43(11): 918-946. doi:10.3760/cma.j.cn112147-20200508-00570. doi: 10.3760/cma.j.cn112147-20200508-00570
[3]	Ratnatunga CN, Lutzky VP, Kupz A, et al. The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Front Immunol, 2020, 11: 303. doi:10.3389/fimmu.2020.00303. doi: 10.3389/fimmu.2020.00303 pmid: 32194556
[4]	Li W, Yazidi A, Pandya AN, et al. MmpL3 as a Target for the Treatment of Drug-Resistant Nontuberculous Mycobacterial Infections. Front Microbiol, 2018, 9: 1547. doi:10.3389/fmicb.2018.01547. doi: 10.3389/fmicb.2018.01547 pmid: 30042757
[5]	Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis, 2016, 45: 123-134. doi:10.1016/j.ijid.2016.03.006. doi: 10.1016/j.ijid.2016.03.006 pmid: 26976549
[6]	Raju RM, Raju SM, Zhao Y, et al. Leveraging Advances in Tuberculosis Diagnosis and Treatment to Address Nontuberculous Mycobacterial Disease. Emerg Infect Dis, 2016, 22(3): 365-369. doi:10.3201/eid2203.151643. doi: 10.3201/eid2203.151643 pmid: 26886068
[7]	Diel R, Nienhaus A, Ringshausen FC, et al. Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease: A Systematic Review. Chest, 2018, 153(4): 888-921. doi:10.1016/j.chest.2018.01.024. doi: 10.1016/j.chest.2018.01.024 URL
[8]	Diel R, Lipman M, Hoefsloot W. High mortality in patients with Mycobacterium avium complex lung disease: a systematic review. BMC Infect Dis, 2018, 18(1): 206. doi:10.1186/s12879-018-3113-x. doi: 10.1186/s12879-018-3113-x
[9]	Preiss L, Langer JD, Yildiz Ö, et al. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Sci Adv, 2015, 1(4): e1500106. doi:10.1126/sciadv.1500106. doi: 10.1126/sciadv.1500106
[10]	Schnippel K, Ndjeka N, Maartens G, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med, 2018, 6(9):699-706. doi:10.1016/S2213-2600(18)30235-2. doi: 10.1016/S2213-2600(18)30235-2 pmid: 30001994
[11]	首都医科大学附属北京胸科医院, 中国防痨协会非结核分枝杆菌分会, 中国防痨杂志》编辑委员会. 非结核分枝杆菌病治疗药品超说明书用法专家共识. 中国防痨杂志, 2020, 42(8): 769-787. doi:10.3969/j.issn.1000-6621.2020.08.002. doi: 10.3969/j.issn.1000-6621.2020.08.002
[12]	Yu X, Gao X, Li C, et al. In Vitro Activities of Bedaquiline and Delamanid against Nontuberculous Mycobacteria Isolated in Beijing, China. Antimicrob Agents Chemother, 2019, 63(8): e00031-19. doi:10.1128/AAC.00031-19. doi: 10.1128/AAC.00031-19
[13]	Pang Y, Zong Z, Huo F, et al. In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China. Antimicrob Agents Chemother, 2017, 61(10): e00900-17. doi:10.1128/AAC.00900-17. doi: 10.1128/AAC.00900-17
[14]	Kim DH, Jhun BW, Moon SM, et al. In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. Antimicrob Agents Chemother, 2019, 63(8): e00665-19. doi:10.1128/AAC.00665-19. doi: 10.1128/AAC.00665-19
[15]	Gil E, Sweeney N, Barrett V, et al. Bedaquiline as Treatment for Disseminated Nontuberculous Mycobacteria Infection in 2 Patients Co-Infected with HIV. Emerg Infect Dis, 2021, 27(3): 944-948. doi:10.3201/eid2703.202359. doi: 10.3201/eid2703.202359 pmid: 33622490
[16]	Erber J, Weidlich S, Tschaikowsky T, et al. Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report. BMC Infect Dis, 2020, 20(1): 365. doi:10.1186/s12879-020-05075-7. doi: 10.1186/s12879-020-05075-7
[17]	Chan WY, Ho PL, To KK, et al. A child with acute myeloid leukemia complicated by calcaneal osteomyelitis due to Mycobacterium abscessus infection after induction chemotherapy successfully salvaged with bedaquiline and clofazimine. Int J Infect Dis, 2021, 103: 9-12. doi:10.1016/j.ijid.2020.10.102. doi: 10.1016/j.ijid.2020.10.102 URL
[18]	Muliaditan M,Della Pasqua O. Evaluation of pharmacokinetic-pharmacodynamic relationships and selection of drug combinations for tuberculosis. Br J Clin Pharmacol, 2021, 87(1):140-151. doi:10.1111/bcp.14371. doi: 10.1111/bcp.14371 URL
[19]	Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax, 2017, 72(Suppl 2): ii1-ii64. doi:10.1136/thoraxjnl-2017-210927. doi: 10.1136/thoraxjnl-2017-210927

含贝达喹啉方案治疗非结核分枝杆菌病三例

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 19

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	丁芹, 张胜康, 任斐, 陈晓红, 胡春梅, 陈薇, 范琳. 耐药肺结核患者的营养状况调查及影响因素分析:一项多中心、大样本研究[J]. 中国防痨杂志, 2023, 45(9): 826-832.
[2]	车贝贝, 王小平, 邱青, 陈诚, 郑旭彬, 赵琦, 徐飚. 2009—2020年江苏省南通市耐多药/利福平耐药肺结核诊疗服务特征的纵向研究[J]. 中国防痨杂志, 2023, 45(9): 864-871.
[3]	杜毓, 张海鹏, 王鹏. 分枝杆菌噬菌体的研究现状及应用进展[J]. 中国防痨杂志, 2023, 45(9): 897-903.
[4]	任汝颜, 薛毅, 梁倩, 黄海荣. 堪萨斯分枝杆菌临床分离株对异烟肼敏感性差异机制研究[J]. 中国防痨杂志, 2023, 45(8): 728-733.
[5]	王嫩寒, 田丽丽, 陈双双, 赵琰枫, 樊瑞芳, 陈昊, 任怡宣, 张洁, 易俊莉, 杨新宇, 于兰, 丁北川, 李传友, 代小伟. 荧光PCR探针熔解曲线技术检测痰标本结核分枝杆菌利福平耐药性的研究[J]. 中国防痨杂志, 2023, 45(6): 583-588.
[6]	王泊宁, 李涛, 陈伟. 耐药结核病经济负担研究进展[J]. 中国防痨杂志, 2023, 45(6): 607-612.
[7]	付亮, 任坦坦, 张培泽, 卢水华. 世界卫生组织《结核病整合指南模块4:耐药结核病治疗2022年更新版》解读[J]. 中国防痨杂志, 2023, 45(4): 336-348.
[8]	朱玉梅, 夏子涵, 李金莉, 何慧珊, 王峰. 多色探针熔解曲线分析技术检测准广泛耐药肺结核的应用价值[J]. 中国防痨杂志, 2023, 45(4): 406-411.
[9]	徐静, 姜爽爽, 郑海伦, 罗萍. 290例耐药肺结核高危人群耐药情况及治疗结果分析[J]. 中国防痨杂志, 2023, 45(3): 323-327.
[10]	王红红, 郭少晨, 周文强, 刘忠泉, 朱慧, 陆宇. 耐药结核病患者利奈唑胺血药浓度对血液系统毒性发生的影响[J]. 中国防痨杂志, 2023, 45(2): 165-171.
[11]	杨虹, 马进宝, 任斐, 李荣, 武延琴, 张耀辉. 15例耐药肺结核患者家庭接触者发展为活动性肺结核的临床特征分析[J]. 中国防痨杂志, 2023, 45(2): 172-180.
[12]	矫晓克, 聂菲菲, 陈晓凤, 郭盼, 刘思. 广泛耐药肺结核并发剥脱性皮炎患者的护理一例[J]. 中国防痨杂志, 2023, 45(12): 1205-1208.
[13]	律彤, 杨云斌, 潘颖, 程玉玉, 李子超, 许琳. 云南省利福平耐药肺结核患者经济负担现状及影响因素分析[J]. 中国防痨杂志, 2023, 45(11): 1031-1037.
[14]	赵爱兰, 余琴, 俞南, 张爱洁, 夏辉, 徐伟. GeneXpert MTB/RIF技术在北京市区级机构提升肺结核病原学阳性检出及利福平耐药筛查中的应用价值[J]. 中国防痨杂志, 2023, 45(11): 1064-1071.
[15]	阮云洲, 张红伟, 李月华, 马樱子, 成诗明, 樊海英, 李仁忠, 赵雁林. 综合医院引入GeneXpert MTB/RIF技术早期发现病原学阳性和耐药肺结核患者的效果分析[J]. 中国防痨杂志, 2023, 45(11): 1072-1077.